Press release
United States Non-Hodgkin Lymphoma Market to Reach $13.5 Billion by 2031 | AbbVie, Inc. , AstraZeneca plc, Bayer AG & Bristol-Myers Squibb Company.
Non-Hodgkin Lymphoma Market
The Non-Hodgkin Lymphoma (NHL) Market covers therapies, including chemotherapy, targeted drugs, and immunotherapies, for the treatment of diverse lymphatic cancers. NHL is characterized by abnormal growth of lymphocytes, leading to immune system impairment. Increasing incidence of lymphoma, advances in personalized medicine, and development of novel immunotherapies drive market growth. Hospitals, cancer treatment centers, and research institutions are primary users. Improved diagnostic techniques and awareness campaigns also contribute to early detection and better treatment outcomes.
π Download Sample Report to Identify Emerging Deals & Opportunities in the Non-Hodgkin Lymphoma Market Landscape:- https://datamintelligence.com/download-sample/non-hodgkin-lymphoma-market?rk
β Non-Hodgkin Lymphoma Market Recent Developments 2025:
United States: Recent Industry Developments in Non-Hodgkin Lymphoma
β In June 2025, the FDA approved tafasitamab (Monjuvi) in combination with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma, offering a new treatment option for patients whose disease has returned or hasn't responded to previous therapies.
β In August 2025, the FDA granted regenerative medicine advanced therapy (RMAT) designation to GLPG5101, a second-generation anti-CD19/4-1BB CAR-T product candidate, for the treatment of patients with relapsed/refractory mantle cell lymphoma.
β In August 2025, the Lymphoma Research Foundation announced its 2025 grant class, awarding 24 research grants totaling $2.7 million to scientists based at leading cancer research institutions, supporting innovative lymphoma and chronic lymphocytic leukemia (CLL) research.
Japan: Recent Industry Developments in Non-Hodgkin Lymphoma
β In February 2025, the Ministry of Health, Labour, and Welfare in Japan approved epcoritamab (Epkinly) for the treatment of patients with relapsed or refractory grade 1 to 3A follicular lymphoma who have received two or more prior lines of therapy.
β In May 2025, Ono Pharmaceutical Co., Ltd. announced that the results from the open-label Phase 2 PROSPECT Study of tirabrutinib would be presented at the 2025 American Society for Clinical Oncology (ASCO) annual meeting, showcasing advancements in NHL treatment.
β In August 2025, the Ministry of Health, Labour and Welfare in Japan approved tazemetostat for relapsed or refractory EZH2 gene mutation-positive follicular lymphoma, providing a new therapeutic option for patients with this specific genetic mutation.
β Non-Hodgkin Lymphoma Market Trends:
The non-Hodgkin lymphoma market is driven by increasing incidence rates of hematologic cancers and the availability of innovative therapies such as monoclonal antibodies, CAR-T cell therapy, and targeted inhibitors. Early diagnosis and growing awareness are further supporting market expansion.
Emerging trends include personalized treatment approaches using genetic and molecular profiling, the rise of outpatient therapy options, and combination treatments aimed at improving survival rates and reducing side effects.
β Non-Hodgkin Lymphoma Market Competitve Landscape:
AbbVie, Inc. (Pharmacyclics LLC), AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company (Celgene Corp.), Gilead Sciences, Inc. (Kite Pharma), Johnson & Johnson (Janssen Biotech, Inc.), Merck & Co., Inc., Novartis AG, Roche Holding AG (F. Hoffmann-La Roche AG), Seagen, Inc. (Seattle Genetics, Inc.), Takeda Pharmaceutical Co., Ltd., and Teva Pharmaceutical Industries Ltd
Research Methodology
We follow a hybrid research approach, combining qualitative insights with rigorous quantitative analysis to deliver reliable and comprehensive market intelligence. Our process begins with extensive secondary research, drawing on trusted industry reports, proprietary databases, and credible market sources. This is then reinforced through targeted primary research, including structured surveys and in-depth interviews with industry leaders, subject matter experts, and key market participants.
π Request a Customized Market Report - Tailored insights to match your business goals: https://datamintelligence.com/customize/non-hodgkin-lymphoma-market
β Segment Covered in the Non-Hodgkin Lymphoma Market:
By Disease Type: B-cell Lymphomas, T-cell Lymphoma
By Drug Class: Monoclonal Antibodies, Antibody-Drug Conjugates, BTK/BCL-2 Kinase Inhibitors, PI3 Kinase Inhibitors, Protease Inhibitors, PD1 Inhibitors, Immunomodulatory Drugs, Chemotherapy Agents, CAR T-Cell Therapy
By Route of Administration: Oral, Parenteral, Others
By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
β This Report Includes:
β Comprehensive go-to-market strategies with actionable insights.
β Unbiased evaluation of overall market performance.
β Deep-dive analysis into development trends, competitive landscape, supply-demand dynamics, YoY growth, benchmarking, vendor mapping, market access, and overall progress.
β Tailored regional and country-level reports with detailed localized analysis available on request.
β Identification of niche segments and high-growth regions presenting strong opportunities.
β Accurate regional forecasts using both top-down and bottom-up approaches.
π Get Corporate Access to Live Non-Hodgkin Lymphoma Industry Intelligence Database: https://www.datamintelligence.com/buy-now-page?report=non-hodgkin-lymphoma-market
β Regional Analysis for Non-Hodgkin Lymphoma Market:
β₯ North America (U.S., Canada, Mexico)
β₯ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
β₯ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
β₯ South America (Colombia, Brazil, Argentina, Rest of South America)
β₯ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
β Frequently asked questions:
β What is the global sales, production, consumption, import, and export value of the Non-Hodgkin Lymphoma Market?
β Who are the key global manufacturers, and what is their operational performance?
β What are the major opportunities and threats in the global Non-Hodgkin Lymphoma Market?
β Which product types or end-users show the most growth potential and market share?
β What challenges and constraints are impacting the Non-Hodgkin Lymphoma Market?
β What sales, marketing, and distribution channels are used globally?
π Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription
β Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.
β Competitive Landscape
β Sustainability Impact Analysis
β KOL / Stakeholder Insights
β Unmet Needs & Positioning, Pricing & Market Access Snapshots
β Market Volatility & Emerging Risks Analysis
β Quarterly Industry Report Updated
β Live Market & Pricing Trends
β Import-Export Data Monitoring
β Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release United States Non-Hodgkin Lymphoma Market to Reach $13.5 Billion by 2031 | AbbVie, Inc. , AstraZeneca plc, Bayer AG & Bristol-Myers Squibb Company. here
News-ID: 4193906 • Views: β¦
More Releases from DataM Intelligence 4market Research LLP
United States Ulcerative Colitis Treatment Market Expected To Reach $11.1 Billio β¦
The Global Ulcerative Colitis Treatment Market reached US$ 6.9 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 11.1 billion by 2031. The global ulcerative colitis treatment market is expected to exhibit a CAGR of 6.3% during the forecast period (2024-2031).
Ulcerative colitis treatment involves medical approaches aimed at reducing inflammation, managing symptoms, and promoting long-term remission in individuals with this chronic inflammatory bowel disease.β¦
United States Cone Beam Computed Tomography Market is expected to reach USD 638. β¦
Global Cone Beam Computed Tomography Market reached USD 369.2 million in 2023 and is expected to reach USD 638.7 million by 2031 growing with a CAGR of 7.2% during the forecast period 2024-2031.
Cone Beam Computed Tomography is a specialized imaging technology that provides three-dimensional scans of the body, primarily used in dental and maxillofacial applications. It offers detailed images with low radiation exposure, aiding in precise diagnosis and treatment planning.β¦
United States Neurovascular Embolization Devices Market Opportunities, Challenge β¦
Global Neurovascular Embolization Devices Market reached US$ 3.7 billion in 2022 and is expected to reach US$ 6.0 billion by 2031, growing with a CAGR of 6.4% during the forecast period 2024-2031.
Neurovascular embolization devices are minimally invasive tools used to treat conditions like aneurysms, arteriovenous malformations (AVMs), and tumors. They include coils, stents, and liquid embolics to block abnormal blood flow or reinforce weak vessel walls. These devices reduce theβ¦
United States Endoscopic Vessel Harvesting Devices Market Outlook: Advancements β¦
The Endoscopic Vessel Harvesting Devices Market is valued at a significant CAGR during the forecast period (2024-2031).
Endoscopic Vessel Harvesting Devices are medical tools used in minimally invasive cardiac and vascular surgeries to carefully extract blood vessels, such as veins or arteries, from the body. These devices allow surgeons to harvest vessels through small incisions, reducing surgical trauma, minimizing scarring, and improving patient recovery compared to traditional open harvesting methods.
π Downloadβ¦
More Releases for Lymphoma
Lymphoma Treatment Market - Liberating Lives from Lymphoma: State-of-the-Art Tre β¦
Newark, New Castle, USA: The "Lymphoma Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Lymphoma Treatment Market: https://www.growthplusreports.com/report/lymphoma-treatment-market/8879
This latest report researches the industry structure, sales, revenue,β¦
Lymphoma Treatment Market - Inspiring Resilience, Shaping Survival: Innovations β¦
Newark, New Castle, USA - new report, titled Lymphoma Treatment Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Lymphoma Treatment market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Lymphoma Treatment market. The report offers an overview of the market, whichβ¦
Lymphoma Therapeutics Market: New Frontiers in Lymphoma Therapeutics | By AMR
Allied Market Research recently said Lymphoma is a type of cancer that affects the lymphatic system, which is an integral part of the body's immune system. While chemotherapy and radiation therapy have been the standard treatment options for lymphoma, recent advances in research have led to the development of new targeted therapies and immunotherapies.
β¦ ππ¨π°π§π₯π¨ππ π
π«ππ πππ¦π©π₯π πππ
πππ©π¨π«π:
https://www.alliedmarketresearch.com/request-toc-and-sample/1448
One such targeted therapy is monoclonal antibodies, which can specifically targetβ¦
Daratumumab Market Precise Analysis , Forecast || key Players- Multiple Myeloma, β¦
Looking at the current market trends as well as the promising demand status of the βDaratumumab Marketβ, it can be projected that the future years will bring out positive outcomes. This research report added by Market Research Hub (MRH) on its online portal delivers clear insight about the changing tendencies across the global market. Readers can gather prime facets connected to the target market which includes product, end-use and application;β¦
T Cell Lymphoma Market T Cell Lymphoma Clinical Pipeline Report
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. T-Cell Lymphoma Market Analysis
2. Mechanism of T-Cell Lymphoma Therapeutics
3. T-Cell Lymphoma Drug Market Overview
3.1 Current Market Scenario
3.2 T Cell Lymphoma Clinical Pipeline Overview
4. T-Cell Lymphoma Drug Market Dynamics
4.1 Favorable Market Parameters
4.2 Commercialization Challenges
5. T-Cell Lymphoma Drug Market Future Prospects
6. T-Cell Lymphoma Drug Clinical Pipeline By Companyβ¦
B Cell Lymphoma Market B Cell Lymphoma Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Introduction to B Cell Lymphoma
1.1 Outline
1.1.1 Non-Hodgkinβs Lymphoma
1.1.2 Hodgkinβs Lymphoma
1.2 Classification of the B Cell lymphoma
1.2.1 Diffuse Large B Cell Lymphoma
1.2.2 Follicular Lymphoma
1.2.3 Mantle Cell Lymphoma
1.2.4 Burkitt Lymphoma
1.3 Stages ofβ¦
